NF-jB transcription factors promote survival in numerous cell types via induction of antiapoptotic genes. Pharmacological blockade of the IKK2 kinase with AS602868, a specific inhibitor that competes with ATP binding, prevented TNF-a-induced NF-jB activation in Jurkat leukemic T cells. While TNF-a by itself had no effect on Jurkat survival, the addition of AS602868 induced cell death, visualized by DNA fragmentation and sub-G1 analysis. A disruption of the mitochondrial potential followed by activation of caspases 9 and 3 was observed in cells treated by the combination TNF-a þ AS602868. Quantitative real-time PCR demonstrated that AS602868 prevented TNF-a induction of the antiapoptotic genes coding for c-IAP-2, Bclx, Bfl-1/A1 and Traf-1. The use of a specific IKK2 inhibitor appears, therefore, as an interesting pharmaceutical strategy to increase the cell's sensitivity towards apoptotic effectors.
Introduction
Transcription factors of the NF-kB family are crucial for the control of immune and inflammatory responses and are involved in the regulation of cell proliferation and survival (Foo and Nolan, 1999) .
NF-kB dimers are maintained inactive in the cytosol by the IkB inhibitory subunits. NF-kB-activating signals stimulate two IkB-specific kinases IKK1 (or IKKa) and IKK2 (or IKKb), which together with the structural and essential component IKKg/NEMO (NF-kB Essential MOdulator) form the IKK complex. Then, the IKKs phosphorylate the IkB-a inhibitory subunit on the Nterminal serines 32 and 36 to target the inhibitor for degradation by the proteasome, in order to free NF-kB to the nucleus (Karin, 1999) . The antiapoptotic role of NF-kB could be demonstrated by the early death occurring from TNF-dependent liver apoptosis in embryos invalidated for the genes coding for IKK2, NEMO or the RelA subunit of NF-kB (reviewed in Karin and Lin, 2002) . Moreover, the expression of a nonphosphorylatable form of the IkB-a subunit, which acts as a super-repressor of NF-kB activation, increased apoptotic responses in various cell lines stimulated by TNF (Van Antwerp et al., 1998) , chemotherapeutic drugs (Wang et al., 1996) , PMA (Busuttil et al., 2002) or TRAIL (Keane et al., 2000) . Given the ubiquitous expression of NF-kB and the important number of inducing stimuli as well as target genes (Pahl, 1999) , it is not surprising that NF-kB is involved in numerous and diverse diseases. Abnormal constitutive activation of NF-kB is observed in various pathological conditions. NF-kB participates in the maintenance of chronic inflammation and asthma, in the survival of cancer cells and their resistance to treatment. NF-kB is also deregulated in neurodegenerative diseases and in diabetes (Baldwin, 2001) . Therefore, NF-kB is an interesting target to pharmaceutically interfere with establishment or progression of these pathological states.
Several compounds have been described as inhibitors of the NF-kB pathway (for a review, see Yamamoto and Gaynor, 2001 ). For instance, aspirin, salicylates and other nonsteroidal anti-inflammatory drugs (NSAID) such as sulindac and sulfasalazine, the sedative drug thalidomide, block IKK activation. The cyclopentone prostaglandins (cyPGs) PGA1 and 15dPGJ2 appear to target IKK2. Glucocorticoids downregulate genes involved in inflammation through negative interaction between the activated glucocorticoid receptor and NFkB. Immunosuppressive agents appeared to act at two different levels: if tacrolimus/FK-506 prevents nuclear translocation of c-Rel, cyclosporine A rather interferes with the proteasome-dependent degradation of IkB. This latter step is also targeted by proteasome inhibitors such as PS-341 and lactacystine. Several natural products were shown to possess NF-kB inhibitory activity. Flavonoids like resveratrol from red wine, polyphenols from green tea, curcumin from curry block NF-kB activation at different levels. However, the main drawback with most of these compounds is their low specificity towards the NF-kB pathway. As a consequence, high doses are required and side effects are likely to occur as it is the case for aspirin in the treatment of chronic inflammation (Yin et al., 1998) . Several more selective inhibitors are now emerging. PS1145, a specific IKK2 inhibitor, has demonstrated interesting properties in inducing apoptosis of NF-kBconstitutive multiple myeloma (MM) cells (Hideshima et al., 2001) . Another IKK2 inhibitor, BMS-345541, displayed NF-kB blocking activity both in vitro and in vivo (Burke et al., 1998) .
We describe here the use of a pharmacological inhibitor, AS602868, which has been selected for its ability to block IKK2. Incubation of Jurkat leukemic T cells with AS602868 revealed the apoptotic properties of TNF, which were visualized by the disruption of mitochondrial potential, and a decrease in antiapoptotic gene transcription, caspase activation and DNA fragmentation. This study paves the way for the use of highly specific NF-kB inhibitors to sensitize leukemic cells to apoptotic effectors.
Results

Characteristics of AS602868
IKK2 is an IkB-specific kinase that transmits most NFkB activation signals. A series of anilinopyrimidine derivatives and ATP competitors were screened in vitro for their inhibitory effect on a constitutively active version of IKK2, IKK2ee, in which two serines of the activation loop were mutated to glutamic acids. These compounds are covered by the patent application PCT WO 02/46171. A first hit was identified (IC 50 ¼ 29 mm) and optimized through chemical modifications to give AS602868 with an IC 50 of 20 nm. AS602868 had no effect on the IKK2 relatives IKK1 (IC50 ¼ 14 mm) or on a large panel of recombinant kinases (data not shown). The compound showed some inhibitory effect on JNK2 (IC 50 ¼ 600 nm). In a series of tests on different cell lines, AS602868 was shown to block phosphorylation of IkB and subsequent NF-kB activation. It could also block the production of TNFa (IC 50 ¼ 300 nm) in LPS-stimulated THP-1 cells as well as ICAM-1 (IC 50 ¼ 800 nm), but not ICAM-2 or VCAM expression in TNF-stimulated HUVEC (data not shown).
AS602868 prevented TNF-and PMA-induced NF-kB activation in Jurkat leukemic T cells Activation of NF-kB was visualized after 1 h of TNF (10 ng/ml) stimulation by its binding to a radioactive probe containing kB sites from the Igk promoter ( Figure 1a , lane 2 compared to unstimulated cells, lane 1). Incubation with increasing doses of AS602868 for 30 min before stimulation with TNF (10 ng/ml) led to a gradual inhibition of NF-kB DNA-binding activity. An inhibitory effect of AS602868 was evident at 0.5 mm (lane 4) and maximal at 10 mm (lane 7). The IC 50 was estimated at 1-2 mm. NF-kB could also be activated in Jurkat cells by the phorbol ester PMA (10 ng/ml) (lane 9). Preincubation with 10 mm AS602868 for 30 min completely blocked PMA-induced NF-kB activation (lane 11). In order to show the specificity of AS602868 for the NF-kB pathway, Jurkat cells were stimulated with TNF or PMA as above without or with prior incubation with 10 mm AS602868 (Figure 1b) . Cellular extracts were analysed by EMSA using an Oct-1-specific probe. No difference in Oct-1 binding could be observed, suggesting that AS602868 did not interfere with the Oct-1 transcription factor.
Jurkat cells were then transfected with a reporter luciferase gene under the control of NF-kB. TNF stimulation led to a 6.3-fold increase in luciferase activity (Figure 1c) , which was strongly decreased by 55 and 75% with, respectively, 2 and 10 mm AS602868. AS602868 (10 mm) had no effect on baseline luciferase activity.
We then assessed the effects of AS602868 on other signaling pathways. Activation of JNK1, JNK2, JNK3, Figure 1 Effect of AS602868 on NF-kB activation. (a) NF-kB activation was visualized by EMSA: Jurkat cells were incubated with indicated doses of AS602868 30 min before stimulation with TNF-a (10 ng/ml) or PMA (10 ng/ml) for 1 h. The total cell extracts were then incubated with a radioactive double-stranded oligonucleotide encompassing the kB site of the Igk promoter. Complexes were separated by nondenaturating electrophoresis followed by autoradiography. (b) Oct-1 activation was visualized by EMSA: Jurkat cells were incubated with AS602868 (10 mm) 30 min before stimulation with TNF-a (10 ng/ml) or PMA (10 ng/ml) for 1 h. Total cell extracts were then incubated with a radioactive doublestranded oligonucleotide encompassing the binding DNA sequence (5 0 -ATGCAAAT-3 0 ) of the Oct-1 transcription factor. Complexes were separated by nondenaturing electrophoresis followed by autoradiography. (c) Luciferase assay: Jurkat cells were transfected with 10 mg of luciferase reporter gene. At 36 h after transfection, cells were treated with the indicated doses of AS602868 30 min before stimulation with TNF-a (10 ng/ml) for 18 h. Luciferase activity was measured as described in Materials and methods. (d) Western blot analysis of active JNK, p38 and ERK kinases: Jurkat cells were stimulated with AS602868 (10 mm) 30 min before stimulation with PMA (10 ng/ml) for 15 min. After lysis, proteins were separated by SDS-PAGE using 10% polyacrylamide gels and blotted on Immobilon membranes that were incubated with anti-phospho-JNK, anti-phospho-p38 anti-phospho-ERK and anti-hsp60 antibodies Pharmacological blockade of NF-jB induces apoptosis C Frelin et al p38, ERK1 and ERK2 was analysed with phosphospecific antibodies. We did not observe a detectable activation of these kinases following TNF stimulation (not shown); however, PMA treatment resulted in a rapid (10 min) and strong activation of ERK1, ERK2, JNK1 and JNK3 ( Figure 1d , lane 3). PMA also induced a lower activation of p38 and an even lower activation of JNK2. Pretreatment with AS602868 prevented the low activation of JNK2 by PMA, but had no action on the other ones (lane 4). AS602868 had no effect by itself on this group of kinases (lane 2). A Western blot of total cell extracts with Hsp60-specific antibodies show that equal amounts of proteins were loaded between the different lanes, and that PMA activation did not change whole-cell protein content (lower panel). These data show that AS602868 is a potent blocker of NF-kB activation in Jurkat cells.
Combination of TNF with AS602868 induced caspasedependent DNA fragmentation
As it is known that NF-kB counteracts caspase activation during signaling through TNFR1, we analysed the effects of the combination of TNF and AS602868 on Jurkat apoptosis. Cell death was first assessed by a sub-G1 analysis. As shown in Figure 2a , 13.7% of the cells were subjected to spontaneous apoptosis. TNF slightly decreased this apoptosis to 10.7%, while AS602868 had little effect, with only a minor increase to 15.7%. By contrast, the combination of TNF with AS602868 induced a strong apoptotic response (42.3%).
Apoptosis was then directly followed by measurement of DNA fragmentation after agarose electrophoresis of cellular DNA in the presence of ethidium bromide ( Figure 2b ). Again, stimulation with TNF (lane 2) or AS602868 (lane 5) did not produce any DNA fragmentation. By contrast, the combination of the two effectors induced DNA laddering, visualized 18 h after addition of the effectors (lanes 3 and 4). AS602868 was slightly more potent to reveal apoptosis when used at 20 mm (lane 4) compared to 10 mm (lane 3). This effect appeared less efficient than the apoptotic response induced by engagement of the death receptor Fas with the monoclonal antibody CH11 (10 ng/ml, lane 6). Addition of the pan-caspase inhibitor Ac-ZVAD-fmk (50 mm) completely prevented the apoptotic response to TNF þ AS602868 (lane 8 compared to lane 7).
These results demonstrate the implication of caspases in the apoptotic response of Jurkat cells to the combination TNF þ AS602868.
Cotreatment of TNF with AS602868 stimulated cellular caspase activation
Caspase activity was first assayed by flow cytometry after incubation with a cell-permeant fluorescent caspase substrate that becomes fluorescent after caspase cleavage (Figure 3a) . Jurkat cells displayed low levels of caspase activity (a: 2.4%). Stimulation for 18 h with 1 mm staurosporine (c) or engagement of Fas (b) led to a strong enhancement of activity of 63 and 57%, respectively. TNF (d) or AS602868 (e: 10 and f: 20 mm) stimulation led to a marginal rise in activity of 4, 4.5, 5.2%, respectively. The combination of AS602868 10 mm with TNF (g) increased caspase activity to 35.2%. An increase of AS602868 concentration to 20 mm did not ameliorate the effect (h: 26.4%).
TNF combined with AS602868 induced disruption of mitochondrial potential and caspase 9 activation
Experiments with different caspase inhibitors pointed to an implication of initiator caspase 9 and effector caspase 3. By contrast, blocking the initiator caspases 8 and 10 that are coupled to death receptors had little to no effect on TNF þ AS602868-induced apoptosis. In addition, we did not detect any increase in caspase 8 activity nor any processing of the procaspase (data not shown) after stimulation with TNF þ AS602868.
We next measured, by flow cytometry, variations in the mitochondrial membrane potential of Jurkat cells using DiOC6 ( Figure 4A ). Without stimulation, 7.7% of cells displayed a low mitochondrial potential (a). Triggering apoptosis with engagement of Fas receptor (b) or incubation with staurosporine (c) led to rupture of the potential in a large number of cells (40.5 and 84.7%, respectively). Neither TNF (d) nor AS602868 at Rupture of the membrane potential precedes cytochrome c release from mitochondria and formation of the apoptosome annunciating activation of caspase 9. Hydrolysis of Ac-LEHD-pNa was used to monitor the activation of caspase 9 on cytosolic extracts prepared 18 h after cell stimulation. While resting, Jurkat cells had no detectable caspase 9 activity ( Figure 4B) ; Fas engagement led to a 48-fold increase in activity. TNF moderately stimulated caspase 9 Activity (18-fold), and inhibition of IKK2 with AS602868 led to intermediate increases (27-and 30-fold with 10 and 20 mm, respectively). Combining TNF and AS602868 showed additive effects (57-fold with 10 mm and 43-fold with 20 mm AS602868). Processing of caspases that led to their activation was measured by Western blotting ( Figure 4B ). TNF or AS602868 stimulations induced a small disappearance of procaspase 9 (lanes 2 and 3, respectively). Combination of AS602868 with TNF induced a slightly more significant disappearance of procaspase 9 (lane 4) that was less significant compared to Fas engagement (lane 5).
Caspase 3 activation is induced in cells treated with TNF and AS602868
Both death receptor and mitochondrial apoptosis pathways funnel into activation of effector caspases such as caspases 3, 6 and 7. The activity of these caspases was analysed by enzymatic assay ( Figure 4C ). Engagement of the Fas receptor led to a strong increase in caspase 3-like activity (495-fold). Cell extracts from apoptotic cells have a 10-fold higher caspase 3 rather than caspase 9 enzymatic activity (1 vs 0.14 nmol pNa/min mg protein). Incubation with TNF and AS602868, 10 or 20 mm, led to moderate increases in activity (110, 175, 190-fold, respectively) . Combination of AS602868 (10 mm) with TNF led to an important increase in activity (315-fold). The effect was more evident when AS602868 was used at 20 mm with TNF (515-fold).
Processing of procaspase 3 was observed by Western blotting when cells were stimulated with CH-11 (lane 5) or AS602868 þ TNF (lane 4). TNF (lane 2) or AS602868 (lane 3) had little effects by themselves.
Although we observed some discrepancies between the levels of enzymatic activities compared to the intensity of caspase processing, these results demonstrate an Figure 3 Effect of AS602868 on caspase activation. Jurkat cells were stimulated 18 h with anti-Fas antibody CH-11 (10 ng/ml), Staurosporine (1 mm) or TNF-a (10 ng/ml). AS602868 was preincubated 30 min before TNF-a stimulation. Specific cleavage of D2R peptide by caspases was visualized by Facs Jurkat cells were incubated for 18 h with TNF-a (10 ng/ml), staurosporine (1 mm) or anti-Fas antibody CH-11 (10 ng/ml). AS602868 was added 30 min before TNF-a stimulation. Mitochondrial membrane depolarization was assessed by loss of DiOC6(3) staining of mitochondria on a flow cytometer. The percentages represent apoptotic cells. (B, C) Measurement of caspase 9 (B) and caspase 3 (C) activation. Cells were pretreated with indicated doses of AS602868 for 30 min before incubation with TNF-a (10 ng/ml) or CH-11 (10 ng/ml) for 18 h. Measurement of caspase enzymatic activity was performed with 50 mg of protein extracts incubated with caspase 9 (Ac-LEHD-pNa) or caspase 3 (Ac-DEVD-pNa) preferential substrates. Hydrolysis was determined after three separate experiments. Results are expressed in nmoles of hydrolysed Ac-pNA/min mg proteins. Western Blot analysis: after lysis, proteins were separated by SDS-PAGE using 10% polyacrylamide gels and blotted on Immobilon membranes that were incubated with anti-procaspase 9, anti-procaspase 3 and anti-hsp60 antibodies Pharmacological blockade of NF-jB induces apoptosis C Frelin et al involvement of the mitochondrial death pathway in apoptosis induced by AS602868 þ TNF.
Combination of TNF with AS602868 decreased transcription of antiapoptotic genes
NF-kB controls the transcription of several genes coding for proteins with antiapoptotic properties. Among them are the caspase inhibitors c-IAP-1 and c-IAP-2, the regulators of mitochondrial membrane potential bcl-x and bfl-1 and the TNFR adaptor TRAF-1. We have analysed the expression of these genes through quantitative real-time PCR using specific primers in the presence of SybrGreen ( Figure 5 ). Incubation of Jurkat cells with TNF for 2 h led only to slight and minor increases in c-IAP-1 (1.45-fold) and bcl-x (1.3-fold) mRNAs, but to higher induction of TRAF-1 (twofold), bfl-1 (2.1-fold) and c-IAP-2 (3.5-fold) mRNAs. Pretreatment with AS602868 before TNF addition had a strong inhibitory effect on c-IAP-2, bcl-x, bfl-1 and TRAF-1 gene expression. The levels of these mRNAs were even below baseline amounts. AS602868 was also observed to decrease the basal expression of these genes, especially for bcl-x and bfl-1, supporting the implication of a low constitutive NF-kB activity in resting Jurkat. By contrast, AS602868 had no effect on c-IAP-1, likely because TNF also had a minimal effect on this gene, which suggests independence towards NF-kB regulation. We were unable to detect any significant decrease in the expression of these proteins by Western blot. Since real-time PCR experiments are more sensitive, it could suggest that small variations in the amount of these proteins could influence cellular homeostasis. Unambiguously, the results show that AS602868 was able to block transcription of a set of NF-kB-dependent survival genes. It is, however, likely that genes other 
Discussion
In this article we show that AS602868, a highly specific IKK2 inhibitor, reveals the apoptotic potential of TNF in Jurkat leukemic T cells. AS602868 was screened in its ability to block IKK2. AS602868 competes with ATP binding and is highly specific for IKK2 in the mm range. It has no inhibitory effect on the related kinase IKK1. AS602868 was found to prevent TNF-induced NF-kB activation completely. No DNA binding of NF-kB or transactivation of a kB-driven reporter gene could be detected in the presence of AS602868 after TNF stimulation. This further demonstrates the predominant role of IKK2 over IKK1 in TNFR signaling, as already suggested by gene invalidation experiments (reviewed in Karin, 1999) .
Upon ligand binding, TNFR1 recruits several adaptor molecules to initiate two interconnected signaling pathways (Ashkenazi and Dixit, 1998; Chen and Goeddel, 2002) . The first one through TRADD and FADD adaptors leads to caspase activation and apoptosis, while the second one via RIP and TRAF-2 links to the IKK complex for NF-kB activation. TNF-induced apoptosis is blocked by NF-kB-regulated expression of several antiapoptotic molecules such as c-IAP-1, c-IAP-2, TRAF-1 and TRAF-2 (Chu et al., 1997; Wang et al., 1998) . The TNF apoptotic potential could also be revealed by the expression of a super-repressor form of the NF-kB inhibitory subunit IkB-a in various cellular models (Sugiyama et al., 1999; Jones et al., 2000) , including Jurkat cells (Van Antwerp et al., 1996) .
Interestingly, the combination of TNF with AS602868 induced DNA fragmentation, a terminal event of apoptosis. This could be prevented by preincubation with the general caspase inhibitor z-VAD. While it was difficult to visualize the activation of caspase 8, which is associated with TNFR1, TNF þ AS602868 stimulated caspase 9 and caspase 3 activity. Caspase 9 activation was preceded by a drop in the mitochondrial transmembrane potential, an event necessary for the exit of cytochrome c out of mitochondria to allow assembly of the apoptosome that contains active caspase 9. Using real-time PCR, we observed that preventing NF-kB activation blocked the induction by TNF of several antiapoptotic genes such as TRAF-1, c-IAP-2, bclxl and bfl-1. Although the exact function of TRAF-1 is not clear, its absence could decrease the magnitude of the NF-kB/antiapoptotic pathway (Bradley and Pober, 2001) . The drop in c-IAP2 expression is likely to facilitate caspases 3 and 7 activation since c-IAP2 was proposed to block the enzymatic activity of these caspases, as well as to induce their ubiquitination and degradation (Salvesen and Duckett, 2002) . Bclx and bfl1/A1 proteins, members of the bcl-2 family, are localized at the external mitochondrial membrane where they exert their antiapoptotic function by inhibiting their proapoptotic homologs such as bad or bax (Gross et al., 1999) . Ectopic expression of bclx and bfl-1 in NFkB activation-deficient A549 human lung adenocarcinoma cells is sufficient for protection towards death from chemotherapy or TNF (Cheng et al., 2000) . In addition, NF-kB-regulated A1/Bfl-1 acts to prevent cytochrome c release and downstream caspases activation in HT1080 fibrosarcoma cells treated with TNF or etoposide (Wang et al., 1999a) . A1/Bfl-1 also controls mitochondrial homeostasis in macrophages (Pagliari et al., 2000) .
Although we have not measured the levels of bclx and bfl-1 proteins, the real-time PCR results suggest that the decrease in these mRNA species could facilitate engagement of the mitochondrial pathway observed after TNF stimulation in the presence of the IKK2 inhibitor. It has been reported that in HT1080 cells, the expression of c-IAP1 and c-IAP2 was sufficient to block etoposide-induced apoptosis while additional expression of TRAF1 and TRAF2 was required to counteract TNF-induced cell death (Wang et al., 1998) . This suggests that different combinations of antiapoptotic proteins are required to counteract different apoptotic stimuli. By regulating a diverse set of antiapoptotic proteins, NF-kB appears to be able to control both the death receptor as well as the mitochondrial pathways of apoptosis and is therefore an important survival pathway in many cell types (Foo and Nolan, 1999) .
Following numerous observations and reports, the concept of cell sensitization to apoptotic signals by means of NF-kB inhibition has emerged. This approach would be particularly useful in the treatment of cancer (Wang et al., 1996) . Indeed, NF-kB is found to be constitutively active in numerous solid tumors as well as in hematologic malignancies (reviewed in . Unregulated active NF-kB could participate in almost all steps of the tumorigenesis process (Hanahan and Weinberg, 2000) . In particular, NF-kB exerts a prosurvival role, and its inhibition often led to apoptosis of cancerous cells (reviewed in Rayet and Ge´linas, 1999) . In addition, NF-kB that is activated by most of the drugs used for cancer chemotherapy (Pahl, 1999) potentiates cellular resistance to treatments. Blockade of NF-kB can thus be considered as a new therapeutic strategy for adjuvant therapy of cancer (Yamamoto and Gaynor, 2001; Garg and Aggarwal, 2002) . In a mouse xenograft model, inhibition of NF-kB by expression of the IkB-a super-repressor in HT1080-transplanted tumor cells induced sensitization of the mice to treatments with TNF or with the topoisomerase poison CPT-11 (Wang et al., 1999b) . Since gene transfer of an IkB-a super-repressor is not easily realizable in human therapy, the discovery of small specific inhibitory molecules is likely to be a major breakthrough. Promising candidates are proteasome inhibitors (Hideshima et al., 2001) , which have already entered clinical trials for both solid tumors and hematological malignancies (Adams, 2002) . Indeed, PS-341 induced apoptosis of drug-resistant MM cells (Hideshima et al., 2001) . Our results show that direct pharmacological targeting of the IKK complex could also be an interesting and promising approach to target NF-kB (Dajee et al., 2003) . It is therefore still a priority to dissect the NF-kB signaling pathway further and to understand its cell type specificity of action. These studies will likely be greatly facilitated by the use of pharmacological specific inhibitors.
Materials and methods
Cell culture, antibodies and reagents
Jurkat cells were maintained in RPMI 1640 medium containing 2 mm glutamine, 50 U/ml penicillin, 50 mg/ml streptomycin, 1 mm pyruvate and 5% fetal calf serum. Anti-caspase 3 and 9 antibodies were from Oncogene Research Products (Boston, MA, USA). Anti-phospho-JNK and anti-phospho-p38-MAPK antibodies were obtained from Cell Signaling Technology (Beverly, MA, USA). Anti-phospho ERK antibody was from Promega (Madison, WI, USA) and anti-hsp60 was from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Staurosporine and regular chemicals were from Sigma-Aldrich (L'Isle d'Abeau, France). Ac-DEVD/LEHD-pNA, Ac-DEVD/IETD-CHO and Z-VAD-FMK were obtained from Biovision Inc (Clinisciences, Montrouge, France). TNF-a was from PeproTech (Rocky Hill, NJ, USA), anti-Fas IgM (CH-11) from Upstate Biotechnology (Lake Placid, NY, USA), DiOC6(3) from Calbiochem (San Diego, USA), D2R reagent from Oncogene research products (Boston, MA, USA), and luciferin was from Promega (Madison, WI, USA).
Electrophoretic mobility shift assays (EMSA)
Total cellular extracts were prepared in Totex lysis buffer (HEPES 20 mm (pH 7.9), NaCl 350 mm, glycerol 20%, NP-40 1%, MgCl 2 1 mm, EDTA 0.5 mm, EGTA 0.1 mm, DTT 1 mm, PMSF 1 mm, Aprotinin 10 mg/ml). Supernatants from a 15 000 g, 10 min centrifugation at 41C were collected. The NF-kB probe used for mobility shift assay was constituted of a synthetic double-stranded oligonucleotide containing the NF-kB-binding site of the Igk promoter (5 0 -GATCCAAGGGACTTTCCATG-3 0 ). The Oct-1 probe was constituted of a synthetic double-stranded oligonucleotide containing the specific DNA-binding sequence of the Oct-1 transcription factor (5 0 -TGTCGAATGCAAATCCACTAGA-3 0 ). The 32 P-end-labeled probes (T4 kinase) were incubated with totex extract samples (20 mg) for 25 min at room temperature. Complexes were then separated by electrophoresis on a 5% nondenaturing polyacrylamide gel in 0.5 Â TBE. Dried gels were subjected to autoradiography.
Luciferase assays
Jurkat cells were transiently transfected by electroporation (320 V, 960 mF) with 10 mg of a luciferase reporter gene controlled by a minimal thymidine kinase promoter and six reiterated kB sites (kBx6 thymidine kinase luc). At 36 h after transfection, cells were stimulated 18 h as indicated.
Determination of subdiploid DNA content
Cells (10 6 /ml) were stimulated as indicated and harvested by centrifugation. Cell cycle analysis was performed by quantifying the DNA content using propidium iodide staining, according to Vindelov et al. (1983) .
DNA fragmentation
After stimulation, cells (10 6 /ml) were collected and lysed with 200 ml of lysis buffer A (10 mm Tris pH 7.5, 1 mm EDTA and 0.2% Triton X-100) 10 min at room temperature. Lysates were treated for 30 min at 371C with 100 mg/ml RNase and then incubated for 30 min with 100 mg/ml proteinase K. Cellular DNA was ethanol-precipitated, dried and resuspended in Tris-EDTA buffer (10 mm Tris and 1 mm EDTA, pH 7.5). DNA was analysed by electrophoresis on 1.2% agarose gels after staining with ethidium bromide.
Measurement of caspase activity by flow cytometry
Jurkat cells (10 6 /ml) were stimulated for 18 h, harvested and incubated with 1 ml of D2R, a cell-permeable fluorescent caspase substrate (Oncogene Research Products, Boston, MA, USA). The fluorescence was measured using the FL-1 channel of a FACScan (Becton Dickinson, Cowley, UK).
Mitochondrial membrane depolarization
Jurkat T cells (10 6 /ml) were stimulated for 18 h, harvested and incubated with 50 nm DiOC6(3) and propidium iodide at 371C for 15 min. Cells were then centrifugated and resuspended in PBS containing 2.5 mm MgCl 2 . DiOC6(3) and PI fluorescence were measured by FACS.
Measurement of caspase activity
After stimulation, cells were lysed for 30 min at 41C in lysis buffer (50 mm HEPES pH 7.5, 150 mm NaCl, 20 mm EDTA, 0.2% Triton X-100, 5 mm DTT, 1 mm PMSF, 10 mg/ml Aprotinin). Lysates were cleared at 10 000 g for 10 min at 41C. Cellular extracts (50 mg) were incubated in a 96-well plate in the presence of 0.2 mm Ac-DEVD-pNA (caspase 3-preferential substrate) or Ac-LEHD-pNA (caspase 9-preferential substrate) (Biovision Inc, Palo Alto, CA, USA) for various time at 371C. Caspase activity was measured at 410 nm and expressed in nmoles of hydrolysed Ac-pNA/ min mg proteins.
Western blot analysis
After stimulation, cells were solubilized in lysis buffer (50 mm HEPES, pH 7.4, 150 mm NaCl, 20 mm EDTA, 100 mm NaF, 10 mm Na 3 VO 4 , 1 mm PMSF, 0.5% NP-40) and incubated for 30 min at 41C. Lysates were centrifuged at 15 000 g for 10 min at 41C and supernatants were adjusted with concentrated SDS sample buffer. Proteins were separated by SDS/PAGE and transferred to Immobilon membranes (Millipore, Bedford, MA, USA) in a Tris (20 mm), glycine (150 mm) and methanol (20%) buffer at 500 mA for 4 h at 41C.
Antibodies were incubated in saturation buffer (50 mm Tris pH 7.5, 50 mm NaCl, 0.15% Tween, 5% BSA) and revealed with a secondary-peroxidase-conjugated antibody followed by ECL detection (Amersham Pharmacia, Saclay, F).
Real-time quantitative PCR
Real-time quantitative RT-PCR analysis was performed on an ABI PRISM 7000 Sequence Detection System using the SYBR Green I Dye (Applied Biosystems, Foster City, CA, USA). After cell treatment, total RNA was isolated using Trizol Reagent (In Vitrogen) based on a method derived by Pharmacological blockade of NF-jB induces apoptosis C Frelin et al Chomczynski and Sacchi (Chomczynski and Sacchi, 1987) . RNA (150 ng) was then reverse transcribed using the SuperScript II reverse transcriptase (In Vitrogen) following the manufacturer's instructions and resuspended in 150 ml final volume. cDNAs (5 ml) or water as control were amplified in duplicate by real-time PCR in a final volume of 25 ml using the SYBR Green Master Mix reagent (Eurogentec) and 300 nm of forward and reverse primers. Primers were designed using the PRIMER Express Software (Applied Biosystems) and are available upon request.
Fluorescence differences were collected by the 7000 ABI thermal cycler during each 601C cycle. Semilogarithmic plots were constructed of delta fluorescence versus cycle number. For analysis, a threshold was set for the change in fluorescence at a point in the linear PCR-amplifications phase (Ct). The Ct values for each gene were normalized to the Ct values for GAPDH. The level of RNA for treated cells compared with the amount in untreated cells was calculated using the equation X ¼ 2 Ct(treated)ÀCt(untreated) (X represents the fold increase in RNA expression).
